Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
139K
-
Shares change
-
+20.8K
-
Total reported value, excl. options
-
$1.43M
-
Value change
-
+$215K
-
Number of buys
-
2
-
Price
-
$10.32
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q4 2023
3 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q4 2023.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 139K shares
of 76.6M outstanding shares and own 0.18% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.64M shares), BAKER BROS. ADVISORS LP (3.88M shares), Redmile Group, LLC (3.26M shares), ARK Investment Management LLC (3.19M shares), MORGAN STANLEY (3.14M shares), Deep Track Capital, LP (3M shares), WASATCH ADVISORS LP (2.75M shares), VANGUARD GROUP INC (2.6M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.39M shares), and Bain Capital Life Sciences Investors, LLC (1.82M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.